Skip to main content
. 2015 Oct 20;7(3):3635–3644. doi: 10.18632/oncotarget.6184

Figure 2. Kaplan–Meier estimates of (A) progression-free survival (PFS) and(B) overall survival (OS) in 416 patients with EGFR mutated NSCLC.

Figure 2

*P < 0.05 for chemotherapy alone versus TKI treatment alone and **P > 0.05 for chemotherapy plus bevacizumab versus TKI treatment alone.